Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Francis Charles Brunicardi

Verified by OpenAlex author ID and NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5048362732, A5112740800; NIH RePORTER profile ID 3065253. Sources: OpenAlex.

Their work

Papers
21 (first author 0, last author 12)
Trials
0
Grants
1
Labs led
3
Collaborators
41
Papers, trials and grants by year

2011: 3 papers · 2012: 3 papers, 1 grant · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 4 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 21

  1. Smart exosomes enhance PDAC targeted therapy. Co-author DOI 10.1016/j.jconrel.2024.02.037↗
  2. Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2020.08.002↗
  3. Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases. Co-author DOI 10.3390/ijms21228679↗
  4. Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia. Co-author DOI 10.3390/ijms21228823↗
  5. Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. Last author DOI 10.3892/or.2020.7810↗
  6. BIRC5 is a target for molecular imaging and detection of human pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.04.036↗
  7. Closing the Disparity in Pancreatic Cancer Outcomes: A Closer Look at Nonmodifiable Factors and Their Potential Use in Treatment. Last author DOI 10.1097/mpa.0000000000001238↗
  8. A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer. Last author DOI 10.1016/j.canlet.2018.01.007↗
  9. KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. Co-author DOI 10.1371/journal.pone.0193644↗
  10. Pancreatic cancer actionable genes in precision medicine and personalized surgery. Last author DOI 10.1016/j.surge.2016.05.002↗
  11. Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.2174/1566524016666151222145551↗
  12. Liposomal insulin promoter-thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice. Last author DOI 10.1016/j.canlet.2015.01.002↗
  13. Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform. Last author DOI 10.1038/cgt.2013.84↗
  14. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. Co-author DOI 10.1002/emmm.201302507↗
  15. Gene profile identifies zinc transporters differentially expressed in normal human organs and human pancreatic cancer. Co-author DOI 10.2174/1566524011313030009↗
  16. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  17. PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. Last author DOI 10.1371/journal.pone.0040452↗
  18. Genomic sequencing of key genes in mouse pancreatic cancer cells. Co-author DOI 10.2174/156652412799218868↗
  19. PDX-1: demonstration of oncogenic properties in pancreatic cancer. Last author DOI 10.1002/cncr.25629↗
  20. Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Co-author DOI 10.1002/cncr.25858↗
  21. Multiple treatment cycles of liposome-encapsulated adenoviral RIP-TK gene therapy effectively ablate human pancreatic cancer cells in SCID mice. Last author DOI 10.1016/j.surg.2010.11.014↗

Grants 1

  1. PDX-1 is a Therapeutic Target for Pancreatic Cancer R01CA095731↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shi‐He Liu · 10 shared papers, 2011–2024 · strength 0.92
  2. John J. Nemunaitis · 11 shared papers, 2011–2024 · strength 0.86
  3. Justin F. Creeden · 5 shared papers, 2019–2024 · strength 0.61
  4. Juehua Yu · 4 shared papers, 2017–2020 · strength 0.37
  5. Donald Rao · 4 shared papers, 2012–2024 · strength 0.35
  6. Robert Erne McCullumsmith · 2 shared papers, 2020 · strength 0.22
  7. Jingyuan Liu · 1 shared paper, 2024 · strength 0.20
  8. James X. Wu · 3 shared papers, 2014–2016 · strength 0.16
  9. William E. Fisher · 5 shared papers, 2011–2013 · strength 0.15
  10. Guisheng Zhou · 4 shared papers, 2011–2016 · strength 0.14
  11. Alexis D. Vick · 1 shared paper, 2019 · strength 0.14
  12. Enrique Rozengurt · 2 shared papers, 2016–2017 · strength 0.14
  13. Marie‐Claude Gingras · 4 shared papers, 2011–2012 · strength 0.11
  14. Jeffrey M. Sutton · 1 shared paper, 2020 · strength 0.10
  15. Cheng Yeh Chen · 1 shared paper, 2020 · strength 0.10
  16. Yu Xu · 1 shared paper, 2020 · strength 0.10
  17. Hongjin Wu · 1 shared paper, 2020 · strength 0.10
  18. Kunhua Wang · 1 shared paper, 2020 · strength 0.10
  19. Lei Zou · 1 shared paper, 2020 · strength 0.10
  20. Jingxuan Yang · 3 shared papers, 2012–2013 · strength 0.09
  21. Qizhi Cathy Yao · 2 shared papers, 2013 · strength 0.06
  22. Xiaobo Cui · 2 shared papers, 2013 · strength 0.06
  23. Xianjun Yu · 2 shared papers, 2013 · strength 0.06
  24. Mei-Fei Li · 2 shared papers, 2012–2013 · strength 0.06
  25. James W. Sinnett‐Smith · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.